Management of hormone refractory prostate cancer: Current standards and future prospects

Journal of Urology

Volumn 160, Issue 4, 1998, Pages 1220-1229

  Oh, William K ^a   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Chemotherapy; Drug therapy; Hormones; Prostatic neoplasms

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; FLUTAMIDE; HYDROCORTISONE; KETOCONAZOLE; MEGESTROL ACETATE; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; STEROID; TAMOXIFEN; VINBLASTINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032323546     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62501-1     Document Type: Article

References (107)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1998. Cancer J. Clin., 48: 6, 1998.
2. Huggins, C., Stevens, R. E. and Hodges, C. V.: Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43: 209, 1941.
3. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med., 321: 419, 1989.
4. Raghavan, D.: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Sem. Oncol., 15: 371, 1988.
5. Scher, H. I., Steineck, G. and Kelly, W. K.: Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142, 1995.
6. Waselenko, J. K. and Dawson, N. A.: Management of progressive metastatic prostate cancer. Oncology, 11: 1551, 1997.
7. Logothetis, C. J., Hoosein, N. M. and Hsieh, J-T.: The clinical and biological study of androgen independent prostate cancer (AI PCa). Sem. Oncol., 21: 620, 1994.
8. Isaacs, J. T. and Coffey, D. S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41: 5070, 1981.
9. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A. and Murphy, G. P.: LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809, 1983.
10. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M. and Lawson, D.: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50: 2275, 1990.
11. Bubley, G. J. and Balk, S. P.: Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Hem. Oncol. Clin. N. Amer., 10: 713, 1996.
12. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. and Balk, S. P.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med., 332: 1393, 1995.
13. Elo, J. P., Kvist, L., Leinonen, K., Isomaa, V., Henttu, P., Lukkarinen, O. and Vihko, P.: Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocr. Metab., 80: 3494, 1995.
14. Visakorpi, T., Hyytinen, E., Kovisto, P., Koivisto, P., Tanner, M., Palmberg, C., Keinänen, R., Tammela, T., Isola, J. and Kallioniemi, O. P.: Amplification of the androgen receptor gene is common in recurrent prostate cancer from patients treated with androgen withdrawal. J. Urol., 153: 379A, abstract 603, 1995.
15. Denmeade, S. R., Lin, X. S. and Isaacs, J. T.: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251, 1996.
16. Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C. and Isaacs, J. T.: Expression of bcl-2 and progression of human and rodent prostate cancers. Clin. Cancer Res., 2: 389, 1996.
17. Haldar, S., Basu, A. and Croce, C. M.: bcl-2 is the guardian of microtubule integrity. Cancer Res., 57: 229, 1997.
18. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
19. Stapleton, A. M. F., Timme, T. L., Gousse, A. E., Li, Q. F., Tobon, A. A., Kattan, M. W., Slawin, K. M., Wheeler, T. M., Scardino, P. T. and Thompson, T. C.: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res., 3: 1389, 1997.
20. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511, 1996.
21. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E. and Frierson, H. F., Jr.: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol., 158: 131, 1997.
22. MacGrogan, D. and Bookstein, R.: Tumor suppressor genes in prostate cancer. Sem. Cancer Biol., 8: 11, 1997.
23. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G. and Klocker, H.: Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392, 1996.
24. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Lang, S., Kato, M., Oefelein, M. G., Mizayano, K., Nemeth, J. A., Kozlowski, J. M. and Lee, C.: Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res., 2: 1255, 1996.
25. Figg, W. D., Ammermann, K., Patronas, N., Steinberg, S. M., Walls, R. G., Dawson, N., Reed, E. and Sartor, O.: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest., 14: 513, 1996.
26. di Sant'Agnese, P. A.: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer, 70: 254, 1992.
27. Smith, P. H., Bono, A., Calais da Silva, F., Debruyne, F., Denis, L., Robinson, P., Sylvester, R., Armitage, T. G. and the EORTC Urological Group: Some limitations of the radioisotope bone scan in patients with metastatic prostate cancer. A subanalysis of EORTC trial 30853. Cancer, 66: 1009, 1990.
28. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61: 195, 1988.
29. Scher, H. I., Mazumdar, M. and Kelly, W. K.: Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst., 88: 1623, 1996.
30. Dawson, N. A. and McLeod, D. G.: The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur. J. Cancer, 33: 560, 1997.
31. Tannock, I. F.: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J. Clin. Oncol., 3: 1013, 1985.
32. Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E. and Friedman, M. A.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol., 3: 827, 1985.
33. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607, 1993.
34. Sella, A., Kilbourn, R., Amato, R., Bui, C., Zukiwski, A. A., Ellerhorst, J. and Logothetis, C. J.: Phase II study of ketoconazole combined with weekly doxoribicin in patients with androgen-independent prostate cancer. J. Clin. Oncol., 12: 683, 1994.
35. Pienta, K. J., Redman, B., Hussein, M., Cummings, G., Esper, P. S., Appel, C. and Flaherty, L. E.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol., 12: 2005, 1994.
36. Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K. and Comis, R.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol., 10: 1754, 1992.
37. Tannock, I. F., Osoba, D., Stockier, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. and Murphy, K. C.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756, 1996.
38. Kantoff, P. W., Conaway, M. and Winer, E.: Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B (9182) trial comparing chemotherapy to best supportive care. Proc. Amer. Soc. Clin. Oncol., 14: 1748, 1996.
39. Scher, H. I., Curley, T., Geller, N., Engstrom, C., Dershaw, D. D., Lin, S. Y., Fitzpatrick, K., Nisselbaum, J., Schwartz, M., Bezirdjian, L. and Eisenberger, M.: Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J. Clin. Oncol., 8: 1830, 1990.
40. Thalmann, G. N., Sikes, R. A., Chang, S. M., Johnston, D. A., von Eschenbach, A. C. and Chung, L. W.: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst., 88: 794, 1996.
41. Tannock, I., Gospodarowiscz, M., Meakin, W., Panzarella, T., Stewart, L. and Rider, W.: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol., 7: 590, 1989.
42. Herr, H. W.: Quality of life in prostate cancer patients. Cancer J. Clin., 47: 207, 1997.
43. Klugo, R. C., Farah, R. N. and Cerny, J. C.: Bilateral orchiectomy for carcinoma of the prostate: response of serum testosterone and clinical response to estrogen therapy. Urology, 17: 49, 1981.
44. Fowler, J. E., Jr. and Whitmore, W. F., Jr.: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol., 126: 372, 1981.
45. Taylor, C. D., Elson, P. and Trump, D. L.: Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 2167, 1993.
46. Hussein, M., Wolf, M., Marshall, E., Crawford, E. D. and Eisenberger, M.: Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J. Clin. Oncol., 12: 1868, 1994.
47. Kelly, W. K. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol., 149: 607, 1993.
48. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566, 1993.
49. Small, E. J. and Vogelzong, N. J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol., 15: 382, 1997.
50. Small, E. J. and Carroll, P. R.: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology, 43: 408, 1994.
51. Dawson, N. A. and McLeod, D. G.: Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J. Urol., 153: 1946, 1995.
52. Small, E. J., Schellhammer, P., Venner, P., Haas, G., Seabaugh, D. R., Patterson, A. L., Klein, E., Wajsman, Z., Furr, B., Nieh, P., Chen, Y., Kennealey, G. T. and Kolvenbag, G.: A double-blind assessment of antiandrogen withdrawal from Casodex (C) or Eulexin (E) therapy while continuing leutinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer. Proc. Amer. Soc. Clin. Oncol., 15: 255, 1996.
53. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Bubley, G. J. and Balk, S. P.: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383, 1997.
54. Blackledge, G. R. P. and Lowery, K.: Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate, 5: 34, 1994.
55. Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L. and Schwartz, M.: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol., 15: 2928, 1997.
56. Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G., DeWolf, W., Balk, S., Taplin, M. E. and Bubley, G. J.: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol., 159: 149, 1998.
57. Kucuk, O., Blumenstein, B., Moinpour, C., Lew, D., Coleman, D., Eisenberger, M. and Crawford, D.: Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulations: a Southwest Oncology Group study (SWOG 9235). Proc. Amer. Soc. Clin. Oncol., 15: 245, 1996.
58. McLeod, D. G.: Antiandrogenic drugs. Cancer, 71: 1046, 1992.
59. Dawson, N. A., Small, E. J., Conaway, M., Winer, E. P., Cooper, M. R., Woliver, T., Ernstoff, M. S. and Vogelsang, N. J. for the Cancer and Leukemia Group B (CALGB): Megestrol acetate in men with hormone-refractory prostate cancer: Prostate specific antigen (PSA) response and anti-androgen withdrawal (AAWD): CALGB 9181. Proc. Amer. Soc. Clin. Oncol., 15: 241, 1996.
60. Osborn, J. L., Smith, D. C. and Trump, D. L.: Megestrol acetate in the treatment of hormone refractory prostate cancer. Amer. J. Clin. Oncol., 20: 308, 1997.
61. Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., Bate, W. W., Respond, R. M. and Oesterling, J. E.: Megestrol acetate for the prevention of hot flashes. New Engl. J. Med., 331: 347, 1994.
62. Gebbia, V., Testa, A. and Gebbia, N.: Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Brit. J. Cancer, 73: 1576, 1996.
63. Wilding, G.: Endocrine control of prostate cancer. Cancer Surv., 23: 43, 1995.
64. Dawson, N. A.: Treatment of progressive metastatic prostate cancer. Oncology, 7: 17, 1993.
65. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M. and Myers, C. E.: Surprising activity of flutamide withdrawal when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer Inst., 86: 222, 1994.
66. Dupont, A., Gomez, J.-L., Cusan, L., Koutsilieris, M. and Labrie, F.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908, 1993.
67. Rochlitz, C. F., Damon, L. E., Russi, M. B., Geddes, A. and Cadman, E. C.: Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother. Pharmacol., 21: 319, 1988.
68. Mahler, C., Verhelst, J. and Denis, L.: Ketoconazole and liazorole in the treatment of advanced prostatic cancer. Cancer, 71: 1068, 1993.
69. Small, E. J., Egan, B., Apodaca, D. and Fippin, L.: Ketoconazole retains significant activity in patients with advanced prostate cancer who have progressed despite flutamide withdrawal. Proc. Amer. Soc. Clin. Oncol., 15: 255, 1996.
70. Horton, J., Rosenbaum, C. and Cummings, F. J.: Tamoxifen in advanced prostate cancer: an ECOG pilot study. Prostate, 12: 173, 1988.
71. Bergan, R. C., Blagosklonny, M. and Dawson, N. A.: Significant activity by high dose tamoxifen in hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 14: A637, 1995.
72. Ferro, M. A., Gillatt, D., Symes, M. O. and Smith, P. J.: High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology, 34: 134, 1989.
73. Robertson, C. N., Roberson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C. S. and Fine, R. L.: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst., 88: 908, 1996.
74. Torti, F. M. and Carter, S. K.: The chemotherapy of prostatic adenocarcinoma. Ann. Intern. Med., 92: 681, 1980.
75. Yagoda, A. and Petrylak, D. P.: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer, 71: 1098, 1993.
76. Kreis, W.: Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest., 13: 296, 1995.
77. Newling, D. W.: The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemother. Pharmacol., Suppl., 30: S90, 1992.
78. Hudes, G.: Estramustine-based chemotherapy. Sem. Urol. Oncol., 15: 13, 1997.
79. Benson, R. C. and Hartley-Asp, B.: Mechanisms of action and clinical uses of estramustine. Cancer Invest., 8: 375, 1990.
80. Amato, R. J., Ellerhorst, J., Bui, C. and Logothetis, C. J.: Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol. Oncol., 1: 168, 1995.
81. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D. and Curley, T.: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J. Urol., 147: 931, 1992.
82. Hudes, G., Roth, B., Loehrer, P., Ramsey, H., Sprandio, J., Entmacher, M., Dugan, W., Ansari, R., Monaco, F., Hanna, M. and Einhorn, L.: Phase III trial of vinblastine versus vinblastine plus estramustine phosphate for metastatic hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 16: 316a, 1997.
83. Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R., Gomella, L., Stern, C. and McAleer, C.: Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Sem. Oncol., 22: 41, 1995.
84. Petrylak, D. P., Shelton, G., Judge, T., O'Connor and MacArthur, R. B.: Phase I trial of docetaxel (D) and estramustine (E) in androgen-insensitive prostate cancer. Proc. Amer. Soc. Clin. Oncol., 16: 310a, 1997.
85. Kreis, W., Budman, D. R., Fetten, J. and Behr, J.: Phase I/II study of the combination of estramustine phosphate (Emcyt) plus docetaxel (Taxotere) in patients with hormone-refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 16: 337a, 1997.
86. Raghavan, D., Cox, K., Pearson, B. S., Coorey, G. J., Rogers, J., Watt, W. H., Coates, A. S., McNeil, E. and Grygiel, J. J.: Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Brit. J. Urol., 72: 625, 1993.
87. Abell, F. L., Wilkes, J. D. and Divers, L.: Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC). Proc. Amer. Soc. Clin. Oncol., 14: 646, 1995.
88. Maulard-Durdux, C., Dufour, B., Hennequin, C., Chrétien, Y., Delanian, S. and Housset, M.: Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer, 77: 1144, 1996.
89. Yagoda, A., Watson, R. C., Natale, R. B., Barzell, W., Sogani, P., Grabstald, H. and Whitmore, W. F.: A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer, 44: 1553, 1979.
90. Frank, S. J., Amsterdam, A., Kelly, W. K., Netto, G., Liebertz, C., Reuter, V. and Scher, H. I.: Platinum-based chemotherapy for patients with poorly differentiated hormone-refractory prostate cancers (HRPC): response and pathologic correlations. Proc. Amer. Soc. Clin. Oncol., 15: 232, 1996.
91. Smith, D. C., Esper, P. S., Todd, R. F. and Pienta, K. J.: Paclitaxel, estramustine and etoposide in patients with hormone refractory prostate cancer (HRPC): a phase II trial. Proc. Amer. Soc. Clin. Oncol., 16: 310a, 1997.
92. Ellerhorst, J. A., Tu, S. M., Amato, R. J., Finn, L., Millikan, R. E., Pagliaro, L. C., Jackson, A. and Logothetis, C. J.: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin. Cancer Res., 3: 2371, 1997.
93. Porter, A. T., McEwan, A. J., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Sathyanarayana, J. R., Yakemchuk, V. N., Thomas, G. M. and Erlich, L. E.: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 25: 805, 1993.
94. Esper, P. S. and Pienta, K. J.: Supportive care in the patient with hormone refractory prostate cancer. Sem. Urol. Oncol., 15: 56, 1997.
95. Dawson, N. A., Cooper, M. R., Figg, W. D., Headlee, D. J., Thibault, A., Bergan, R. C., Steinberg, S. M., Sausville, E. A., Myers, C. E. and Sartor, O.: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer, 76: 453, 1995.
96. Kelly, W. K., Curley, T., Leibertz, C., Dnistrian, A., Schwartz, M. and Scher, H. I.: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol., 13: 2208, 1995.
97. Small, E. J., Marshall, M. E., Reyno, L., Natale, R., Meyer, M., Lenehan, P., Chen, L. and Eisenberger, M.: Superiority of suramin + hydrocortisone over placebo + hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 17: 308a, 1998.
98. Jungwirth, A., Schally, A. V., Pinski, J., Halmos, G., Groot, K., Armatis, P. and Vadillo-Buenfil, M.: Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Brit. J. Cancer, 75: 1585, 1997.
99. Figg, W. D., Thibault, A., Cooper, M. R., Reid, R., Headlee, D., Dawson, N., Kohler, D. R., Reed, E. and Sartor, O.: A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer, 75: 2159, 1995.
100. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G. and Simons, J. W.: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379, 1996.
101. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O. and Kliewer, S. A.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270: 12953, 1995.
102. Sedlacek, H. H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A. and Sausville, E.: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143, 1996.
103. Haldar, S., Chintapalli, J. and Croce, C. M.: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253, 1996.
104. Campbell, S. C.: Advances in angiogenesis research: relevance to urological oncology. J. Urol., 158: 1663, 1997.
105. Zetter, B. R.: Angiogenesis and tumor metastasis. Ann. Rev. Med., 49: 407, 1998.
106. Boasberg, P., Harbaugh, M., Eisenberger, M., Harris, J., Langleben, A., Ahmann, F., Roth, B. and Berkheimer, M.: Marimastat in patients with hormone refractory prostate cancer. Proc. Amer. Soc. Clin. Oncol., 16: 316a, 1997.
107. Sanda, M. G.: Biological principles and clinical development of prostate cancer gene therapy. Sem. Urol. Oncol., 15: 43, 1997.